Jaswant Goyal1, Zafer Yab Khan2, Prerna Upadhyaya3, Barkha Goyal4, Shipra Jain5. 1. Demonstrator, Department of Pharmacology, MG Medical College & Hospital , Jaipur, India . 2. Professor, Department of Pharmacology, MG Medical College & Hospital , Jaipur, India . 3. Associate Professor, Department of Pharmacology, MG Medical College & Hospital , Jaipur, India . 4. Postgraduate Student, Department of Biochemistry, MG Medical College & Hospital , Jaipur, India . 5. Assistant Professor, Department of Pharmacology, MG Medical College & Hospital , Jaipur, India .
Abstract
INTRODUCTION: Hypertension is one of the major public health challenges worldwide. Angiotensin receptor blockers (ARBs) and Calcium channel blockers (CCBs) are among the first line antihypertensive drugs. However, optimal treatment strategies in mild to moderate hypertensives who failed to achieve blood pressure (BP) control with low-dose mono-therapy are not well established. This study was done to compare efficacy and safety of high dose mono-therapy of Amlodipine, Telmisartan and their low dose combination in mild to moderate hypertensives who failed to achieve BP control with low dose mono-therapy of either drug. MATERIALS AND METHODS: A total of 96 patients, fulfilling inclusion and exclusion criteria were enrolled in the study after obtaining informed consent. Patients were randomized into three treatment groups i.e. Telmisartan 80 mg, Amlodipine 10 mg and low dose combination of Telmisartan 40 mg +Amlodipine 5 mg once daily for two months. The systolic BP, Diastolic BP, and ADRs were recorded at 0, 2, 4, 8 weeks. RESULTS: In the present study, significant reduction of mean systolic blood pressure (SBP) and mean diastolic blood pressure (DBP) was seen in all the three treatment groups. Low dose combination of Amlodipine 5 mg and Telmisartan 40 mg showed statistically significant reduction in SBP as compared to Telmisartan 80 mg mono-therapy and in DBP as compared to Amlodipine 10 mg mono-therapy. Maximum adverse drug reactions (ADRs) were reported in Amlodipine mono-therapy group, like ankle oedema, constipation, headache and fatigue. DISCUSSION AND CONCLUSION: In term of BP control, low-dose combination therapy appears a better therapeutic approach than high-dose mono-therapy.
RCT Entities:
INTRODUCTION:Hypertension is one of the major public health challenges worldwide. Angiotensin receptor blockers (ARBs) and Calcium channel blockers (CCBs) are among the first line antihypertensive drugs. However, optimal treatment strategies in mild to moderate hypertensives who failed to achieve blood pressure (BP) control with low-dose mono-therapy are not well established. This study was done to compare efficacy and safety of high dose mono-therapy of Amlodipine, Telmisartan and their low dose combination in mild to moderate hypertensives who failed to achieve BP control with low dose mono-therapy of either drug. MATERIALS AND METHODS: A total of 96 patients, fulfilling inclusion and exclusion criteria were enrolled in the study after obtaining informed consent. Patients were randomized into three treatment groups i.e. Telmisartan 80 mg, Amlodipine 10 mg and low dose combination of Telmisartan 40 mg +Amlodipine 5 mg once daily for two months. The systolic BP, Diastolic BP, and ADRs were recorded at 0, 2, 4, 8 weeks. RESULTS: In the present study, significant reduction of mean systolic blood pressure (SBP) and mean diastolic blood pressure (DBP) was seen in all the three treatment groups. Low dose combination of Amlodipine 5 mg and Telmisartan 40 mg showed statistically significant reduction in SBP as compared to Telmisartan 80 mg mono-therapy and in DBP as compared to Amlodipine 10 mg mono-therapy. Maximum adverse drug reactions (ADRs) were reported in Amlodipine mono-therapy group, like ankle oedema, constipation, headache and fatigue. DISCUSSION AND CONCLUSION: In term of BP control, low-dose combination therapy appears a better therapeutic approach than high-dose mono-therapy.
Entities:
Keywords:
Amlodipine; Hypertension; Low dose combination of telmisartan and amlodipine; Telmisartan
Authors: Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He Journal: Lancet Date: 2005 Jan 15-21 Impact factor: 79.321
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: Osvaldo Kohlmann; Wille Oigman; Décio Mion; João Carlos Rocha; Marco Antonio Mota Gomes; Natalino Salgado; Gilson Soares Feitosa; Ernesto Dallaverde; Artur Beltrame Ribeiro Journal: Arq Bras Cardiol Date: 2006-02-13 Impact factor: 2.000
Authors: Thomas W Littlejohn; Claudio R Majul; Rafael Olvera; Mary Seeber; Maureen Kobe; Robert Guthrie; Wille Oigman Journal: J Clin Hypertens (Greenwich) Date: 2009-04 Impact factor: 3.738